Clinical trials: Familial Alzheimer Disease (FAD)
Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
The study will be conducted in 2 blinded parts (Part 1 and Part 2). In Part 1, study participants who are mutation carriers will receive active donanemab and non-mutation carriers will receive placebo-donanemab for up to 18…
- Conditions
- Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease, Alzheimers Disease
- Trial name
- NCT06996730
- Testing
- Donanemab, RG6289
- Where
- Colombia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Banner Health
Alzheimer Disease, Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)
A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage.
- Conditions
- Alzheimer Disease, Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)
- Trial name
- NIO-SILK (NCT06372821)
- Testing
- NIO752
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 10 people
- Sponsor
- University College, London
Alzheimer Disease, Alzheimer Disease 1
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Alzheimer's disease.
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT04100889
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Alzheimer Disease
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease
This substudy will evaluate the effect of crenezumab on the longitudinal tau burden in a subgroup of preclinical Presenilin1 (PSEN1) E280A mutation carriers and non-carriers, who were enrolled in study NCT01998841 (GN28352).
- Trial name
- NCT03977584
- Testing
- Crenezumab, [^18F]GTP1
- Where
- Colombia
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort
This study consists of 2 periods: [1] Study Period A - evaluating the efficacy and safety of Crenezumab versus Placebo in participants who carry the PSEN1 E280A autosomal-dominant mutation and do not meet the criteria for mild…
- Trial name
- NCT01998841
- Testing
- Crenezumab
- Where
- 4 sites in Colombia
- Volunteers
- 252 people
- Sponsor
- Genentech, Inc.
Familial Alzheimer Disease (FAD), PSEN1 Mutation
Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease
The goal of this clinical trial is to learn about safety and efficacy of bromocriptine in familial Alzheimer's disease with presenilin 1 mutations.
- Trial name
- REBRAnD (NCT04413344)
- Testing
- Bromocriptine Mesilate
- Where
- 8 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Kyoto University
Alzheimer Disease 3, Epilepsy
Improvement Effect of Lacosamide and Levetiracetam on Cognitive in Alzheimer's Disease Patients With Epilepsy
Participants will perform Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), Alzheimer's disease assessment scale-cognitive section (ADAS-Cog), Hamilton Anxiety Scale…
- Trial name
- NCT05969054
- Testing
- Lacosamide 100 mg, Levetiracetam 250mg
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Xiangya Hospital of Central South University
Alzheimer Disease, Alzheimer Disease 1
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)
This is a randomized, double-blind, sham-controlled pivotal study of sensory stimulation in subjects with mild to moderate AD. Up to approximately 670 subjects will be treated with either Active or Sham investigational device…
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- HOPE (NCT05637801)
- Testing
- Spectris™ AD - Active
- Where
- 68 sites in United States
- Volunteers
- 673 people
- Sponsor
- Cognito Therapeutics, Inc.
Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset
China Cognition and Aging Study
The aim of this study is to establish and perfect the China Cognition and Aging Study (China COAST) cohort, to clarify the epidemiology, influencing factors, genetic characteristics, pathogenesis, disease characteristics and…
- Conditions
- Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset, Familial Alzheimer Disease (FAD), Vascular Dementia (VaD)
- Trial name
- COAST (NCT03653156)
- Where
- 65 sites in China
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Capital Medical University
Dementia, Alzheimer Disease 1
Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease
This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.
- Conditions
- Dementia, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT03806478
- Testing
- APH-1105
- Volunteers
- 60 people
- Sponsor
- Aphios
Alzheimer Disease, Familial Alzheimer Disease (FAD)
The Chinese Familial Alzheimer's Network
This research will establish and continuously improve the FAD research network in conjunction with multi-center institutions nationwide.
- Trial name
- CFAN (NCT03657732)
- Where
- 65 sites in China
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Capital Medical University